Background: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this diversity exists at a biological level. 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 147 serum mediators, total IgE levels, and 130 allergen-specific IgE levels. Population heterogeneity was assessed by using principal component analysis, followed by unsupervised k-means cluster analysis of the principal components. Results: Patients with AD showed pronounced evidence of inflammation compared with healthy control subjects. Principal component analysis of data on sera from patients with AD revealed the presence of 4 potential clusters. Fifty-seven principal components described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest principal components delivered 4 distinct clusters of patients with AD. Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14. Cluster 2 had low SASSAD scores with the lowest levels of IFN-a, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor. Cluster 3 had high SASSAD scores with the lowest levels of IFN-b, IL-1, and epithelial cytokines. Cluster 4
Atopic dermatitis (AD) is the most common inflammatory skin disease worldwide. The underlying pathologic mechanisms are incompletely described, and AD presents clinically with a broad range of features. Different clinical AD phenotypes have been described that are based on characteristics, such as age of onset, or the presence of other atopic diseases, such as allergic rhinitis and asthma. 1, 2 Despite efforts to better understand AD pathogenesis through defining phenotypical subsets (eg, patients with intrinsic compared with those with extrinsic AD), 3, 4 it remains poorly understood. Indeed, it is hypothesized that AD cannot be explained by one mechanism alone; this hypothesis also suggests that it is unlikely that newly developed biological drugs that target highly specific biological axes of the immune or skin barrier development systems will be effective in all patients with AD. Consistent with this thinking, recent clinical trials with the anti-IL-4 receptor a mAb dupilumab have been very encouraging, but it is clear that this treatment is not equally effective in all patients and that an alternative therapeutic approach will be required in some patients. Indeed, in the recently published phase 3 dupilumab trials, the primary outcome of reduction in Investigator's Global Assessment score to 0 or 1 occurred in 38% of patients. 5 In the exciting future of personalized health care, it is critical to be able to provide the right drug to the right patient. Hence it is essential to gain better insight into the heterogeneous nature of the disease at the biological level. We hypothesized that the heterogeneity in AD could be described through differential serum biomarker profiles and set out to test this using a broad Luminex panel (Multiplex Luminex immunoassays; Luminex, Riverside, Calif) assessed in a large 200-patient cohort of moderate and severe AD patients. When these data were subjected to principal component analysis (PCA), followed by unsupervised cluster analysis, we were able to identify 4 patient clusters with distinct serum biomarker profiles and overlapping clinical phenotypes that might represent distinct disease endotypes.
METHODS

Study design
We hypothesized that AD is heterogeneous at the biological level of individual serum inflammatory mediators. To test this hypothesis, we measured 147 analytes (see Table E1 in this article's Online Repository at www.jacionline. org) in the sera of 200 patients with moderate-to-severe AD and 30 healthy control subjects without AD by using Luminex-based multiplex immunoassays; total and allergen-specific IgE levels (Immuno-solid Phase Allergen Chip [ISAC]) were also assessed. Clinical characteristics were extracted from the patients' electronic files. PCA of serum biomarker data (including total IgE levels) followed by unsupervised k-means cluster analysis was used to identify heterogeneous patient clusters. ISAC data were not included in PCA analysis because they were comprised of semiquantitative data only. Detailed methods related to measurement of serum mediators and statistical analysis are available in the Methods section in this article's Online Repository at www.jacionline.org.
Patients and control subjects
The rule of thumb adopted for sizing populations for multivariate principal components is 5 times the number of independent variables measured. 6 The number of independent variables mentioned above is the number of unique variables that do not correlate to any other variable. Our experience from asthma research 7 suggests that analytes are often highly correlated; extrapolating this suggested that within 150 analytes, there are likely to be about 20 unique independent variables. According to the guidance above, the required sample size was 100 (5 3 20) patients with moderate and 100 with severe AD.
From a biobank of more than 1000 patients with AD, 200 patients who were all treated with only topical corticosteroids were selected. To select patients, they were first grouped based on the six area, six sign atopic dermatitis (SASSAD) severity score 8 into 6 groups: patients with moderate AS with SAS-SAD scores ranging from (1) 15 to 20, (2) 21 to 25, and (3) 26 to 30 and patients with severe AD with SASSAD scores ranging from (4) 31 to 35, (5) 36 to 40, and (6) greater than 40. Then, because previous analysis revealed that sex and age were factors of interest in patients with AD, 9 the 6 groups were normalized on sex and age before final selection. Final selection included equal numbers from each of the 6 SASSAD score groups. Thirty healthy control subjects without a previous history of AD, allergic asthma, or allergic rhinoconjunctivitis and approximately age and sex matched to the patients with AD were recruited from the University Medical Center Utrecht and included in the study.
All patients with AD were given a diagnosis of AD according to the criteria of Hanifin and Rajka. 10 However, patients with AD present with a wide spectrum of clinical features that can vary considerably between them. From our observations in the clinic, we have the impression that there are 2 mutually exclusive subsets of patients: those with a predominantly chronic lichenified eczema and those with a predominantly erythematous eczema. To correlate clusters with clinical features, we labeled patients as having chronic lichenified eczema or erythematous eczema.
The protocols of this study were approved by the Institutional Review Board of the University Medical Center Utrecht (Utrecht, The Netherlands), adhering to the Declaration of Helsinki Principles.
RESULTS
Patients' demographics, clinical characteristics, and serum biomarker profiles
From the 200 serum samples, 7 were different time points from the same patients and hence were not included in the final patient selection. Therefore a total of 193 patients with moderate-to-severe AD were studied, and this groups was made up of 95 patients with moderate and 98 patients with severe AD. Thirty adult control subjects with no history of AD, allergic asthma, or allergic rhinitis were also recruited for the study, although they were older than the patients with AD Table I .
For all patients and healthy control subjects, serum concentrations of 147 analytes were determined by using the multiplex immunoassay. Levels of serum total and specific IgE, periostin, dipeptidyl peptidase 4, and anti-Staphylococcus aureus a toxin IgG were also measured. A bioassay was used to measure the neutralizing ability of S aureus a toxin antibodies in sera from patients with AD and healthy control subjects. For technical reasons, IL-19, growth-regulated oncogene-alpha (GRO-a), and scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) levels could not be measured in healthy control subjects. In patients with AD, all analytes were detectable (see Tables E2-E7 in this article's Online Repository at www.jacionline.org). In sera from healthy control subjects, IL-3, leukemia inhibitory factor, eotaxin, I309, and macrophage colony-stimulating factor were undetectable (see Tables E2-E7 ). In general, patients with AD had a clearly different serum biomarker profile from healthy control subjects, with large upregulation of key inflammatory biomarker families in patients with AD versus control subjects, including T H 2, epithelial, and IL-1 family cytokines, as well as total and specific IgE (see Tables E4-E8 in this article's Online Repository at www.jacionline.org).
PCA and unsupervised cluster analysis reveals 4 clusters of patients with AD
To test the hypothesis that AD was biologically heterogeneous, we performed PCA on the Box-Cox transformed serum biomarker data set, which revealed the likely presence of 4 clusters (Fig 1, A) . Summation of variances showed that the first 57 principal components described 90% of the data set variance (Fig 1, B) . Therefore the first 57 principal components were included in an unsupervised k-means cluster analysis, which delivered 4 AD clusters (Fig 1, C , and see Video E1 in this article's Online Repository at www.jacionline.org).
Characterization of AD clusters
AD cluster membership or control status was added back to the complete data set, and all variables were compared by cluster versus the healthy control subjects. Clinical characteristics (not included in the cluster analysis) were analyzed between the 4 clusters and are shown in Table II . Averages of serum analytes per cluster were calculated and tabulated to characterize the clusters (see Tables E2 and E3 ). As expected, more frequent sensitization to allergen components measured by using ISAC was seen in patients with AD compared with healthy control subjects (see Table E8 ). However, no clear differences in sensitization patterns were observed between the patient clusters (see Table E9 in this article's Online Repository at www. jacionline.org). Measurement of anti-S aureus a toxin IgG was used as a systemic marker of S aureus exposure in patients with AD; however, this showed no difference between clusters. Total IgE levels also did not show any significant differences between the 4 clusters (see Table E3 ). Key characteristics, both clinical and serum profiles, for each AD cluster are described below.
Cluster 1 (high SASSAD score/BSA, pulmonary and activation-regulated chemokine [PARC]/tissue inhibitor of metalloproteinases 1 [TIMP-1]/soluble CD14 [sCD14] high) represented 23% of the AD population and was 59% female. Cluster 1 patients had a geometric mean age of 31.2 years (95% CI, 27.7-35.1 years) and, alongside cluster 3, the highest severity score. The cluster 1 geometric mean SASSAD score was 35.3 (95% CI, 31.9-39.0), which was greater than that of clusters 2 and 4, and the cluster 1 median BSA score was 54 (Q1-Q3, 40.4-69), which was greater than that of clusters 2 and 3. Cluster 1 was defined uniquely by having the highest levels of PARC, TARC, and TIMP-1 (both greater than clusters 2, 3, and 4 and healthy control subjects) and was distinguished from clusters 2, 3, and 4 by having the highest level of sCD14 (see Table E2 ). Clinically, cluster 1, alongside cluster 3, had the highest incidence of asthma (54% vs 53%, respectively), which was greater than that in clusters 2 and 4 (43% vs 36%, respectively), although cluster 1 was unique in having the highest incidence of asthma and rhinitis (47% vs 38%, 38%, 32%, respectively). Cluster 1 patients had a similar frequency of erythematous phenotype to cluster 4 (15% vs 19%, respectively), which was greater than that observed in clusters 2 and 3 (8% and 4%, respectively). Cluster 1 patients Categorical variables are presented as counts and percentages, log-normally distributed variables are presented as geometric means (95% CIs), and nonnormally distributed data are presented as medians (25th-75th percentiles) of logged data. Superscript letters after measure of central tendency are groups that are significantly different at a P value of less than .05 as follows: <mod, <sev, <HC, statistically less than patients with moderate AD, patients with severe AD, and healthy control subjects, respectively; >mod, >sev, >HC, statistically greater than patients with moderate AD, patients with severe AD, and healthy control subjects, respectively. Absence of superscript letters denotes no statistical difference between groups. NA, Not applicable. also shared with cluster 4 patients the highest frequency of infant-onset AD (57% vs 56%, respectively), which surpassed those in clusters 2 and 3 (45% and 42%, respectively; Table II) . Cluster 2 (low SASSAD score, IFN-a/TIMP-1/vascular endothelial growth factor [VEGF] low) represented 29% of the AD population and was 56% female. Cluster 2 patients were younger than cluster 3 patients, with a geometric mean age of 28.1 years (95% CI, 25.3-31.1 years) and, alongside cluster 4, the lowest severity score. The cluster 2 geometric mean SASSAD score was 25.5 (95% CI, 23.2-28), which was lower than those of both clusters 1 and 3, and cluster 2 median BSA was 36 (Q1-Q3, 24-54), which was less than that of cluster 1 (Table II) . Cluster 2 was uniquely defined by having the lowest levels of TIMP-1 (lower than those of clusters 1, 3, and 4 and healthy control subjects), VEGF, and IFN-a (lower than clusters 1, 3, and 4 but higher than the healthy control subjects). Clinically, cluster 2 patients had a similar frequency of lichenified phenotype as cluster 3 (74% vs 76%, respectively), which was greater than (Table II) , and averages of serum analytes per cluster were calculated and tabulated to characterize the clusters (see Tables E2 and E3 ). This figure shows characterization of the 4 AD clusters. MIG, Monokine-induced by interferon-g; TWEAK, TNF-like weak inducer of apoptosis.
that observed in clusters 1 and 4 (60% and 43%, respectively). Cluster 2 patients also had the highest frequency of childhood-onset AD (47%), which surpassed those in clusters 1, 3, and 4 (36%, 43%, and 30%, respectively).
Cluster 3 (high SASSAD score, IFN-b/IL-1/epithelial cytokine low) was the largest cluster, representing 33% of the AD population, and was 53% female. Cluster 3 patients were older than both cluster 2 and 4 patients, with a geometric mean age of 35.0 years (95% CI, 31.4-39.0 years). Cluster 3, alongside cluster 1, had the highest severity score. The cluster 3 geometric mean SASSAD score was 32.1 (95% CI, 29.7-34.8), which was higher than those of both clusters 2 and 4. Cluster 3 median BSA was 40.5 (Q1-Q3, 27-54), which was less than that of cluster 1. Cluster 3 was defined uniquely by having the lowest levels of IFN-b, IL-1 receptor antagonist, IL-26, monokine-induced by interferon-g (MIG) (all less than control subject and clusters 1, 2, and 4), eotaxin, IL-1b, IL-1 receptor type 1, IL-4, IL-9, IL-12, IL-15, IL-21, IL-25, IL-33, triggering receptor expressed on myeloid cells, thymic stromal lymphopoietin (TSLP; all more than control subjects but less than clusters 1, 2, and 4), cutaneous T cellattracting chemokine, IL-1a, GRO-a, IL-19, and IL-37 (all less than clusters 1, 2, and 4). Clinically, cluster 3 patients had the lowest frequency of erythematous phenotype (4% vs 15%, 8%, 19%, respectively), as well as, together with cluster 4, the highest frequency of adult-onset AD (12% vs 5%, 4%, 11%, respectively; Table II ). Cluster 3 patients also had the highest frequency of comorbid asthma alone (15% vs 7%, 6%, and 4%, respectively), as well as, together with cluster 1, the highest frequency of comorbid asthma alone or with rhinitis (53% vs 54%, 43%, and 36%, respectively; Table II) .
Cluster 4 (female predominant, low SASSAD score, IL-1/IL-4/ IL-13, and TSLP high) represented 15% of the AD population and was the most female-predominant group (68%). Cluster 4 patients were younger than cluster 3 patients, with a geometric mean age of 27.4 years (95% CI, 23.3-32.1 years) and, alongside cluster 2, the lowest severity score. The cluster 4 geometric mean SASSAD score was 25.8 (95% CI, 22.4-29.7), which was lower than those of both clusters 1 and 3, and cluster 4 median BSA was 43.5 (Q1-Q3, 33-55). Cluster 4 was defined uniquely as profoundly inflamed by having the highest levels of B lymphocyte chemoattractant, elastase, eotaxin, erythropoietin receptor, fibroblast growth factor b, granulocyte chemotactic protein 2, GM-CSF, IFN-g, IL-1a, IL-1b, IL-1 receptor antagonist, IL-1 receptor type 1, IL-4, IL-8, IL-9, IL-11, IL-13, IL-15, IL-17, IL-19, IL-20, IL-21, IL-37, leukocyte-associated immunoglobulin-like receptor 1, LIGHT, monocyte chemoattractant protein 3, macrophage inflammatory protein 1a, nerve growth factor, sclerostin, soluble VEGF receptor 1, TNF-a, TNF-b, triggering receptor expressed on myeloid cells, TSLP, X-C motif chemokine ligand 1 (all more than clusters 1, 2, and 3 and healthy control subjects), GRO-a, IFN-b, IL-2, and placental growth factor (all more than clusters 1, 2, and 3 and see Table E2 ). Clinically, cluster 4 patients had the highest frequency of erythematous phenotype (19% vs 15%, 8%, and 4%, respectively). Cluster 4 patients also had the lowest frequency of comorbid asthma (36% vs 54%, 43%, and 53%, respectively) and the highest frequency of no comorbid asthma or rhinitis (36% vs 23%, 26%, and 20%, respectively; Table II) .
DISCUSSION
AD is recognized as a complex and highly heterogeneous disease characterized by a diverse clinical manifestation, but little work has been performed to characterize the biological differences underlying this clinical heterogeneity. Classically, clinical characteristics, such as disease severity, age of onset, and the presence of atopic comorbidities, are used to divide AD into different disease phenotypes. 2 However, these phenotypic characteristics do not seem to relate to specific disease mechanisms and have not yet given us new insight into the underlying pathology of disease. It has become increasingly clear that AD is not only heterogeneous based on clinical characteristics but that different underlying pathophysiologic processes are found in different subgroups of patients. 11, 12 The primary goals of our study were first to test whether AD is heterogeneous at the level of the serum biomarker profile and then to describe this heterogeneity and its relationship to clinical presentation.
To the best of our knowledge, this is the first study that classifies patients with AD on serum biomarker-based clusters. We used a purely data-driven approach to cluster serum biomarker profiles in a population of patients with moderate-to-severe AD. This approach revealed 4 distinct clusters of patients with AD, showing that adult AD is a truly heterogeneous disorder. Each cluster has a distinct profile of soluble mediators that together might indicate these clusters are driven by distinct but as yet unidentified underlying pathways.
Classification based on subgroups defined by distinct functional or pathophysiologic mechanisms is termed endotyping. 13, 14 The 4 distinct patient clusters that we identified in this study could represent endotypes that have unique biology driving the pathogenesis of disease. Further biological studies and interventional trials will be needed to confirm the endotype of each cluster. However, it is hoped that endotypes could be used to target specific therapies in future clinical trials and daily practice.
Each cluster in our analysis is characterized by certain serum biomarkers and clinical characteristics that are significantly differentially expressed. Two of the clusters, 1 and 3 (SASSAD scores of 35 and 32), were relatively more severe than clusters 2 and 4 (SASSAD scores of 25 and 26). Of the more severe clusters, cluster 1 was delineated from the others by having the highest levels of PARC, TARC, TIMP-1, and sCD14. In contrast, cluster 3 was defined by the lowest levels of host defense-associated molecules, including IFN-b and MIG, the IL-1 family members IL-1a and IL-1b, the T H 2 cytokines IL-4 and IL-9, and the key immune-initiating epithelial cytokines IL-25, IL-33, and TSLP. Of the less severe clusters, cluster 2 was defined by having the lowest levels of TIMP-1, VEGF and IFN-a, whereas cluster 4 was defined by being female predominant (68%) and having the highest levels of multiple inflammatory cytokines, including the IL-1 family; the T H 2 cytokines IL-4, IL-9, and IL-13; and the epithelial cytokine TSLP.
Moving beyond individual cluster-differentiating patterns of mediator expression, there were also interesting commonalities across the clusters (Fig 1, C) . Patients in clusters 1 and 4, representing 48% of patients, had particularly high T H 2 cytokine levels and an erythematous skin phenotype and would hypothetically represent ideal patients for T H 2-targeting drugs that are currently being tested, including the anti-IL-4 receptor a antibody dupilumab and the anti-IL-13 antibodies lebrikizumab and tralokinumab (NCT02755649, NCT02340 234, and NCT02347176). [15] [16] [17] Moreover, given the recent success of dupilumab in AD trials, the biomarker expression of these 2 clusters could directly relate to the underlying pathophysiologic processes in these patients.
Clusters 2 and 3, representing 52% of patients, share a T H 2 cytokine-low and pauci-inflammatory mediator state (analogous to that seen in patients with T H 2-low asthma), 18 as well as presenting with a greater frequency of the lichenified skin phenotype. These clusters would hypothetically represent patient groups that are not ideal for T H 2-targeting drugs, and a more comprehensive biological characterization of disease mechanisms in these patients will be required to allow generation of more tailored therapeutics.
The statistically nonsignificant association of erythematous skin with a strong epithelial cytokine and T H 2 phenotype and the association of lichenified skin with a weak epithelial cytokine and T H 2 phenotype is intriguing and could imply a mechanistic link (Fig 1, C) . Whether this mechanistic link is real or simply represents biomarkers of an as yet unidentified biological mechanism remains to be elucidated. Similarly, understanding how the underlying biology of patients in clusters 2 and 3 could drive the lichenification process requires further investigation.
Taken together, the clusters found in our study, approximately 48% ''T H 2 high'' and 52% ''T H 2 low,'' are consistent with recent phase 3 data from dupilumab in patients with AD 5 demonstrating that 62% of patients did not achieve the primary end point of reduction in Investigator's Global Assessment scores and would support the use of biomarkers to identify optimal dupilumab responders in future trials. Although both clusters 1 and 4 have high T H 2 cytokine levels, they can be clearly differentiated from each other through high expression of PARC and TSLP, respectively. This might indicate a pathophysiologic process in cluster 4 in which higher levels of TSLP could drive a more pruritic phenotype. 19 Thus patients in cluster 4 could represent those patients who would respond best to new anti-TSLP biologics currently being tested.
The identification of phenotypes, leading to hypothetical endotypes, based on cluster analyses of immune mediators has been demonstrated in patients with other diseases, including asthma, 7, 20, 21 chronic obstructive pulmonary disease, 7 and chronic rhinosinusitis. 22 If such endotyping can be confirmed with interventional studies, it will prove useful with the introduction of new targeted therapies because patients with different endotypes might respond differently to the same treatment. Subgrouping patients based on serum biomarker levels and blood eosinophil counts has already proved useful in asthmatic patients, in whom anti-IL-13 therapy appears to be most effective in the specific subgroup of patients with high serum levels of periostin. 23, 24 Similarly, quantifying blood eosinophil counts in asthmatic patients has facilitated the identification of those patients that best respond to IL-5 axis-targeting drugs, such as benralizumab. 25 The ability to endotype patients with AD might contribute to precision medicine by allowing treatment to be tailored for individual patients.
14 This would not only be beneficial for patients but would also reduce health care costs. 26 We expect that biomarker analyses might become essential in all clinical trials to enable better selection of patient populations and optimize therapy.
Data presented in this study also confirm that there is systemic inflammation in patients with AD, supporting the hypothesis that AD is a systemic disorder. The high expression of many inflammatory cytokines and chemokines in sera of patients with AD resulted in clear differences in biomarker expression profiles between patients with AD and healthy control subjects, as shown in Tables E4 and E5 . The concept of AD as a systemic disorder was recently highlighted in a meta-analysis of data from the AD transcriptome. 27 Given that 3 population-based studies have shown an association between adult AD, cardiovascular disease, and increased heart attacks, 28 systemic inflammation in patients with AD might, as in patients with psoriasis, contribute to cardiovascular disease. 29 The results of this study warrant further investigation. One limitation of this study is the inability to identify a clear association between the 4 clusters and clinical characteristics other than severity scores, such as the presence of allergic asthma or rhinitis and age of disease onset. The patients in this study were selected solely based on disease severity (SASSAD score), sex, and age, and no other clinical characteristics peculiar to AD were considered for selecting patients. Additionally, detailed clinical characterization was not available for every patient. Therefore the absence of an association between the clusters and other clinical characteristics might be due to missing data or the consequence of the unbalanced presence of these clinical characteristics across the hypothetical endotypes. It also highlights the significant challenges in identifying endotypes with underlying pathophysiologic mechanisms based on clinical features, such as age of onset or the presence of other atopic diseases. The fact that we could not find any clear differences in sensitization patterns based on 150 specific IgE levels between the patient clusters strengthens this hypothesis. This would also be in accordance with the findings of dupilumab trials in which treatment effects were found to be similar in both intrinsic and extrinsic AD patient groups. 3, 4 Additionally, the present study is retrospective, and its findings will require further validation of the utility of serum biomarkers for clustering AD. The clusters that were identified in this study should be confirmed in an independent patient population in a prospective study. We anticipate that prospective studies, including more biomarkers, might reveal more subgroups of patients and provide more insight into the association with clinical characteristics. Also, a longitudinal study might provide us additional insights into the stability of biomarkers in a patient over time. The current study focused on serum biomarkers, which might represent the downstream effects of certain underlying pathways. Interventional clinical trials will help to confirm whether the serum biomarkers associated with each cluster directly relate to a pathologic mechanism and thus confirm clusters as specific endotypes. Future studies should follow a multilayered approach, integrating high-throughput data from genomics, transcriptomics, lipomics, and proteomics with extensive clinical data, to more precisely endotype patients and identify underlying pathways.
In summary, in a population of patients with moderate-tosevere AD, we have identified 4 clearly differentiated clusters illustrating the heterogeneity of AD at the molecular and phenotypic level. Each cluster is characterized by a specific serum biomarker profile, implying that each of these clusters is driven by a distinct underlying pathway and might represent endotypes. The identification of these endotypes through future interventional studies with specific pathway-neutralizing agents could enable more specific targeting of the underlying disease pathways and contribute to more personalized treatment strategies for patients with AD in the future.
Key messages
d In a population of patients with moderate-to-severe AD, we have identified 4 distinct clusters based on serum biomarker profiles, illustrating the biological heterogeneity of AD.
d The patient clusters identified could represent underlying endotypes that have unique biology driving disease pathogenesis and could therefore lead to a more personalized approach for biologic therapeutic use.
d The clear differences in biomarker expression profiles between patients with AD and healthy control subjects indicates systemic inflammation in patients with AD.
